- Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference
- Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
- Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting
- Prelude Therapeutics to Participate in Barclays Global Healthcare Conference
- Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024
- Prelude Therapeutics Announces $25 Million Private Placement
- Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results
- Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
- Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference
More ▼
Key statistics
On Friday, Prelude Therapeutics Inc (PRLD:NSQ) closed at 3.85, -36.10% below its 52-week high of 6.03, set on Jun 06, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.84 |
---|---|
High | 3.94 |
Low | 3.59 |
Bid | 3.46 |
Offer | 5.50 |
Previous close | 3.87 |
Average volume | 47.89k |
---|---|
Shares outstanding | 54.93m |
Free float | 51.11m |
P/E (TTM) | -- |
Market cap | 211.48m USD |
EPS (TTM) | -1.88 USD |
Data delayed at least 15 minutes, as of May 31 2024 21:00 BST.
More ▼